자발적 부작용보고자료를 이용한 의약품 상호작용 실마리 정보 탐색 방법

키워드

참고문헌 (44)

1. Choi JS, "Drug-drug interaction", Korean Soc Hosp Pharm, 15(2), pp.149~159 (1998)
2. Kim SH, "Guidelines for safe drug use", Korean J Med, 96(3), pp.225~235 (2021)[DOI]
3. Lee JS, "Recent trends in drug interaction studies based on drug metabolism", Yakhak Hoej, 64(1), pp.8~20 (2020)[DOI]
4. Gosho M, "Risk of hypoglycemia after concomitant use of antidiabetic, antihypertensive, and antihyperlipidemic medications : A database study", J Clin Pharmacol, 58(10), pp.1324~1331 (2018)[DOI]
5. Sohn KH, "Clinical usefulness evaluation of computerized drug-drug interaction program", J Korean Soc Health Syst Pharm, 32(4), pp.299~307 (2015)[DOI]
6. Pirmohamed M, "Adverse drug reactions", BMJ, 316(7140), pp.1295~1298 (1998)[DOI]
7. Roblek T, "Drug-drug interaction software in clinical practice : A systematic review", Eur J Clin Pharmacol, 71(2), pp.131~142 (2015)[DOI]
8. Rekić D, "Clinical drug–drug interaction evaluations to inform drug use and enable drug access", J Pharm Sci, 106(9), pp.2214~2218 (2017)[DOI]
9. Wang X, "Propensity score-adjusted three-component mixture model for drug-drug interaction data mining in FDA Adverse Event Reporting System", Stat Med, 39(7), pp.996~1010 (2020)[DOI]
10. Cai R, "Identification of adverse drug-drug interactions through causal association rule discovery from spontaneous adverse event reports", Artif Intell Med, 76, pp.7~15 (2017)[DOI]
11. Won HH, "Detecting drug interaction signal of concomitant use of warfarin and statins using Korea adverse event reporting system database", Yakhak Hoej, 67(1), pp.15~22 (2023)[DOI]
12. Norén GN, "A statistical methodology for drug–drug interaction surveillance", Stat Med, 27(16), pp.3057~3070 (2008)[DOI]
13. Chung SY, "The role of the KIDS for enhancing drug safety and risk management in Korea", J Korean Med Assoc, 55(9), pp.861~868 (2012)[DOI]
14. Kim HM, "Analysis of adverse events reporting patterns and signal detection for pediatric patients in the Korean spontaneous reporting data", J Pharmacoepidemiol Risk Manag, 5(1), pp.40~45 (2012)
15. Kim SJ, "Pharmacovigilance organization and activity of WHO-UMC", J Pharmacoepidemiol Risk Manag, 7(1), pp.1~6 (2014)
16. Kim HH, "Big data analysis technology trends for predicting drug side effects", Korea Inform Proc Soc Rev, 24(5), pp.14~21 (2017)
17. Park JY, "The contraindication of comedication drugs and drug utilization review", J Korean Med Assoc, 55(5), pp.484~490 (2012)[DOI]
18. Thakrar BT, "Detecting signals of drug–drug interactions in a spontaneous reports database", Br J Clin Pharmacol, 64(4), pp.489~495 (2007)[DOI]
19. Antonazzo IC, "Myopathy with DPP-4 inhibitors and statins in the real world : Investigating the likelihood of drug–drug interactions through the FDA adverse event reporting system", Acta Diabetol, 57(1), pp.71~80 (2020)[DOI]
20. Van Puijenbroek EP, "Signalling possible drug–drug interactions in a spontaneous reporting system : Delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole", Br J Clin Pharmacol, 47(6), pp.689~693 (1999)[DOI]
21. Yang H, "Drug-drug interactions detection from online heterogeneous healthcare networks", 2014 IEEE International Conference on Healthcare Informatics, pp.7~16 (2014)
22. Kim S, "Predicting drug-target interactions using drugdrug interactions", PLoS One, 8(11), pp.e80129~ (2013)[DOI]
23. Jeong E, "Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system", Front Pharmacol, 13, pp.938552~ (2022)[DOI]
24. Harpaz R, "Mining electronic health records for adverse drug effects using regression based methods", Proceedings of the 1st ACM International Health Informatics Symposium 2010, pp.100~107 (2010)
25. Skrondal A, "Interaction as departure from additivity in case-control studies : A cautionary note", Am J Epidemiol, 158(3), pp.251~258 (2003)[DOI]
26. Noguchi Y, "Review of statistical methodologies for detecting drug–drug interactions using spontaneous reporting systems", Front Pharmacol, 10, pp.1319~ (2019)[DOI]
27. DuMouchel W, "Empirical bayes screening for multi-item associations", Proceedings of the seventh ACM SIGKDD international conference on Knowledge discovery and data mining 2001, pp.67~76 (2001)
28. Abdo A, "Novel data-mining methodologies for detecting drug-drug interactions : A review of pharmacovigilance literature", Adv Environ Sci Dev Chem, 20, pp.301~314 (2014)
29. Szarfman A, "Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database", Drug Saf, 25(6), pp.381~392 (2002)[DOI]
30. Muñoz MA, "Data mining of the US FDA’s adverse events reporting system database to evaluate drug–drug interactions associated with statin-induced rhabdomyolysis", Pharm Med, 30, pp.327~337 (2016)[DOI]
31. Hauben M, "A quantitative analysis of the spontaneous reporting of congestive heart failure-related adverse events with systemic anti-fungal drugs", J Clin Pharmacol, 53(7), pp.762~772 (2013)[DOI]
32. Almenoff JS, "Disproportionality analysis using empirical Bayes data mining : A tool for the evaluation of drug interactions in the post-marketing setting", Pharmacoepidemiol Drug Saf, 12(6), pp.517~521 (2003)[DOI]
33. Baker RA, "Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database : A systematic Bayesian signal detection analysis", Psychopharmacol Bull, 42(1), pp.11~31 (2009)
34. Noguchi Y, "Comparison of signal detection algorithms based on frequency statistical model for drug-drug interaction using spontaneous reporting systems", Pharm Res, 37(5), pp.86~ (2020)[DOI]
35. Qian Y, "A computerized system for detecting signals due to drug–drug interactions in spontaneous reporting systems", Br J Clin Pharmacol, 69(1), pp.67~73 (2010)[DOI]
36. Strandell J, "Rhabdomyolysis a result of azithromycin and statins : An unrecognized interaction", Br J Clin Pharmacol, 68(3), pp.427~434 (2009)[DOI]
37. Gosho M, "Utilization of chi-square statistics for screening adverse drug-drug interactions in spontaneous reporting systems", Eur J Clin Pharmacol, 73(6), pp.779~786 (2017)[DOI]
38. Bonneterre V, "Application of pharmacovigilance methods in occupational health surveillance : Comparison of seven disproportionality metrics", Saf Health Work, 3(2), pp.92~100 (2012)[DOI]
39. Hauben M, "Decision support methods for the detection of adverse events in post-marketing data", Drug Discov Today, 14(7-8), pp.343~357 (2009)[DOI]
40. Kasliwal R, "Spontaneous reporting in pharmacovigilance : Strengths, weaknesses and recent methods of analysis", J Clin Prev Cardiol, 1(1), pp.20~23 (2012)
41. Chen RT, "The vaccine adverse event reporting system(VAERS)", Vaccine, 12(6), pp.542~550 (1994)[DOI]
42. Egberts AC, "Use of measures of disproportionality in pharmacovigilance : Three Dutch examples", Drug Saf, 25(6), pp.453~458 (2002)[DOI]
43. "Nedrug signal alert"[URL]
44. Lu Z, "Information technology in pharmacovigilance : Benefits, challenges, and future directions from industry perspectives", Drug Healthc Patient Saf, 1, pp.35~45 (2009)[DOI]

관련 논문AI추천